RBC Capital analyst Gregory Renza maintained a Buy rating on aTyr Pharma (LIFE – Research Report) on November 9 and set a price target of $19.00. The company’s shares closed yesterday at $1.12.
According to TipRanks, Renza is a 3-star analyst with an average return of 0.6% and a 38.46% success rate. Renza covers the Healthcare sector, focusing on stocks such as Seagen, Alpine Immune Sciences, and IDEAYA Biosciences.
Currently, the analyst consensus on aTyr Pharma is a Strong Buy with an average price target of $22.33, which is a 1,893.75% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.70 and a one-year low of $1.15. Currently, aTyr Pharma has an average volume of 180.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
aTyr Pharma (LIFE) Company Description:
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
